Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) EBT Margin (2016 - 2025)

Cytosorbents (CTSO) has disclosed EBT Margin for 14 consecutive years, with 36.97% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT Margin fell 483.0% year-over-year to 36.97%, compared with a TTM value of 36.69% through Sep 2025, down 4017.0%, and an annual FY2024 reading of 51.09%, down 2488.0% over the prior year.
  • EBT Margin was 36.97% for Q3 2025 at Cytosorbents, up from 44.0% in the prior quarter.
  • Across five years, EBT Margin topped out at 167.57% in Q4 2023 and bottomed at 150.42% in Q3 2022.
  • Average EBT Margin over 5 years is 53.07%, with a median of 47.57% recorded in 2024.
  • The sharpest move saw EBT Margin surged 18736bps in 2023, then crashed -21514bps in 2024.
  • Year by year, EBT Margin stood at 93.14% in 2021, then skyrocketed by 79bps to 19.79% in 2022, then skyrocketed by 947bps to 167.57% in 2023, then plummeted by -128bps to 47.57% in 2024, then grew by 22bps to 36.97% in 2025.
  • Business Quant data shows EBT Margin for CTSO at 36.97% in Q3 2025, 44.0% in Q2 2025, and 16.94% in Q1 2025.